Diabetes PubMed

  • Increase font size
  • Default font size
  • Decrease font size
Home Diabetes Types Gestational Capillary blood glucose screening (Accu-Chek Advantage) for gestational diabetes

Capillary blood glucose screening (Accu-Chek Advantage) for gestational diabetes

J Med Assoc Thai. 2009 Oct;92(10):1268-72.

Srimaekarat T.

Department of Obstetrics and Gynecology, Trang Regional Hospital, Muang, Trang, Thailand. This e-mail address is being protected from spambots. You need JavaScript enabled to view it

OBJECTIVE: To determine optimal threshold of capillary blood glucose screening (Accu-Chek Advantage) for gestational diabetes. STUDY DESIGN: A cross-sectional analytical study. MATERIAL AND METHOD: Capillary and venous blood of pregnant women who attended the antenatal clinic at Trang Regional Hospital between August 2007 and May 2008 were collected for glucose testing (by approach of American Diabetes Association's Fourth International Workshop-Conference on Gestational Diabetes) at one hour after taking 50 gm glucose. The glucose values of Accu-Check Advantage were compared with the standard venous plasma glucose. The receiver operator characteristic (ROC) curve was created to determine the optimal threshold of the capillary blood test screening for gestational diabetes. RESULTS: A total of 816 pregnant women were enrolled in the present study. Their capillary blood glucose values and plasma glucose values were checked with the Accu-Chek Advantage and the central laboratory chemistry analyzer respectively. The good correlation between capillary blood glucose and plasma glucose values was found (correlation coefficient = 0.80, 95% CI 0.77-0.82). There was a significant difference in the average values of capillary blood and plasma blood (134.1 vs. 122.7 mg/dl, respectively). When the data were analyzed by ROC curve, the optimal level of capillary blood by Accu-Chek Advantage for performing a 100 gm oral glucose tolerance test was 140 mg/dl (reference plasma glucose level of at least 140 mg/dl). The sensitivity specificity likelihood ratio for a positive test result and likelihood ratio for a negative test result were 93.8%, 83.6%, 5.71 and 0.07, respectively. The potential advantages of capillary blood glucose screening are simple to use, cheap and convenient. CONCLUSION: Accu-Chek Advantage is suitable for screening gestational diabetes using the optimal threshold capillary glucose level of 140 mg/dl.

PMID: 19845232

 

Bookmark and Share

Popular Diabetes PubMed Citations

Newsflash

Millions unite for diabetes awareness on World Diabetes Day 2010
Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight. World Diabetes Day is the best opportunity there is to draw attention to the silent killer that is diabetes.
 
Bristol-Myers Squibb Foundation Launches $100 Million Initiative
The Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office - in their homes and communities - and for the course of their disease.
 
New global survey reveals more than one in three patients fail to take insulin as prescribed
More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77% of physicians estimate that in reality this number could be as high as six doses*, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM) survey, released today by Novo Nordisk.
 

Facebook Page Twitter Subscribe to Latest Diabetes PubMed facts... by Email RSS

Subscribe

Get Diabetes PubMed facts delivered by email. Enter your email address:


Delivered by FeedBurner

Who's Online

We have 4 guests online

Sponsored Links

PharmaNews.eu
PharmaNews.eu - the dynamic European pharmaceutical news engine.
www.pharmanews.eu

Advertise here